The Effect of Subcutaneous Infusions of 3 Doses of DG3173 on Growth Hormone Levels in Untreated Acromegalics

Inclusion Criteria: * Men, women of non child-bearing potential, or women of child-bearing potential who either abstain from sexual intercourse, have a sterile partner or practice two medically approved, non-hormonal methods of contraception * Diagnosis of acromegaly of pituitary origin * Have an age-adjusted insulin-like growth factor type 1 (IGF-1) concentration ≥1.2 times the upper limit of normal range on at least one measurement in the 12 months prior to screening (Visit 1) AND a second raised value screening * Have at least one random hGH level of ≥5 μg/L in the 12 months prior to screening AND a second raised value at screening * Have given written informed consent * Ability to comply with the requirements of the protocol for the study Exclusion Criteria: * Previous specific treatment for acromegaly in the 12 months prior to screening, including somatostatin analogues (SSAs); surgery; radiotherapy and pegvisomant * Treatment with dopamine agonists in the 3 months prior to screening * Uncontrolled hypertension * Type I diabetes mellitus, poorly-controlled type II diabetes mellitus (glycosylated haemoglobin \[HbA1c\] ≥7.5%) and patients requiring insulin treatment * Gallstones or gravel that could cause biliary obstruction * Hyperprolactinaemia * Participation in a clinical study within 60 days prior to screening * Receipt of blood, blood products or plasma derivatives 60 days prior to screening * Body mass index (BMI) below 22 or above 37 kg/m2 * Pregnancy, lactation or use of any hormonal based contraceptives * Concomitant intake of corticosteroids or levodopa * A history of active alcohol abuse or drug addiction * Positive viral serology screening result for hepatitis B surface antigen, antibodies to hepatitis C virus, or human immunodeficiency virus type 1 and 2 * Evidence or suspicion of tumour expansion * Clinically significant abnormality in screening ECG in the opinion of the Investigator * Any clinically significant abnormal in screening laboratory safety test (biochemistry, haematology and dipstick urinalysis) in the opinion of the Investigator * Any disease which in the Investigator's opinion would exclude the patient from the study